FI922593A0 - Inhibition av papillomavirus med çantisenseç-oligonukleotider. - Google Patents

Inhibition av papillomavirus med çantisenseç-oligonukleotider.

Info

Publication number
FI922593A0
FI922593A0 FI922593A FI922593A FI922593A0 FI 922593 A0 FI922593 A0 FI 922593A0 FI 922593 A FI922593 A FI 922593A FI 922593 A FI922593 A FI 922593A FI 922593 A0 FI922593 A0 FI 922593A0
Authority
FI
Finland
Prior art keywords
papillomavirus
oligonucleotide
çantisenseç
oligonucleotider
med
Prior art date
Application number
FI922593A
Other languages
English (en)
Other versions
FI922593A (fi
Inventor
Stanley T Crooke
Christopher K Mirabelli
David J Ecker
Lex M Cowsert
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of FI922593A0 publication Critical patent/FI922593A0/fi
Publication of FI922593A publication Critical patent/FI922593A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/708Specific hybridization probes for papilloma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI922593A 1989-12-04 1992-06-04 Inhibition av papillomavirus med çantisenseç-oligonukleotider. FI922593A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44519689A 1989-12-04 1989-12-04
PCT/US1990/007067 WO1991008313A1 (en) 1989-12-04 1990-12-03 Antisense oligonucleotide inhibition of papillomavirus

Publications (2)

Publication Number Publication Date
FI922593A0 true FI922593A0 (fi) 1992-06-04
FI922593A FI922593A (fi) 1992-06-04

Family

ID=23767951

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922593A FI922593A (fi) 1989-12-04 1992-06-04 Inhibition av papillomavirus med çantisenseç-oligonukleotider.

Country Status (11)

Country Link
EP (1) EP0503002B1 (fi)
JP (1) JPH05501058A (fi)
KR (1) KR960012069B1 (fi)
AT (1) ATE163973T1 (fi)
AU (1) AU650257B2 (fi)
BR (1) BR9007892A (fi)
CA (1) CA2070664C (fi)
DE (1) DE69032134T2 (fi)
FI (1) FI922593A (fi)
HU (1) HUT62944A (fi)
WO (1) WO1991008313A1 (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447839A (en) * 1988-09-09 1995-09-05 Hoffmann-La Roche Inc. Detection of human papillomavirus by the polymerase chain reaction
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5620963A (en) * 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5587361A (en) * 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5635488A (en) * 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US5599797A (en) * 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5661134A (en) * 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5654284A (en) * 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5607923A (en) * 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
WO1995028942A1 (en) * 1994-04-26 1995-11-02 Genta Incorporated Antisense oligomers for inhibiting human papillomaviruses
US5750341A (en) * 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
US6458940B2 (en) * 1995-06-06 2002-10-01 Hybridon, Inc. HPV-specific oligonucleotides
FR2758725B1 (fr) * 1997-01-29 1999-04-02 Pasteur Institut Composition comprenant une proteine e2 de papillomavirus ou une sequence de nucleotides codant pour une proteine e2 de papillomavirus
EP2212420A2 (en) * 2007-11-05 2010-08-04 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases as antiviral agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
WO1988006634A1 (en) * 1987-02-26 1988-09-07 The University Of Sydney A method of detection of carcinogenic human papillomavirus
US4849332A (en) * 1987-05-26 1989-07-18 Life Technologies, Inc. Human papillomavirus 35 nucleic acid hybridization probes and methods for employing the same
US4849331A (en) * 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same
US4849334A (en) * 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) * 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
FR2629458B2 (fr) * 1987-07-31 1991-08-09 Ire Celltarg Sa Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain
US4886741A (en) * 1987-12-09 1989-12-12 Microprobe Corporation Use of volume exclusion agents for the enhancement of in situ hybridization
DE3838269A1 (de) * 1988-11-11 1990-05-17 Behringwerke Ag Nachweis humaner papillomavirus dna und ihrer expression in zervix-abstrichen
US5027693A (en) * 1989-11-24 1991-07-02 Allied-Signal Inc. Combination diaphragm and valve body
AU7302191A (en) * 1990-01-30 1991-08-21 Children's Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides

Also Published As

Publication number Publication date
BR9007892A (pt) 1992-09-29
ATE163973T1 (de) 1998-03-15
CA2070664A1 (en) 1991-06-05
CA2070664C (en) 2000-08-08
EP0503002A1 (en) 1992-09-16
KR960012069B1 (ko) 1996-09-12
JPH05501058A (ja) 1993-03-04
HUT62944A (en) 1993-06-28
WO1991008313A1 (en) 1991-06-13
EP0503002A4 (en) 1993-03-10
DE69032134D1 (de) 1998-04-16
FI922593A (fi) 1992-06-04
DE69032134T2 (de) 1998-07-23
AU7175691A (en) 1991-06-26
HU9201865D0 (en) 1992-09-28
EP0503002B1 (en) 1998-03-11
AU650257B2 (en) 1994-06-16

Similar Documents

Publication Publication Date Title
EP0637316A4 (en) ANTISENSE OLIGONUCLEOTIDE INHIBITORS OF PAPILLOMAVIRUS.
FI922593A0 (fi) Inhibition av papillomavirus med çantisenseç-oligonukleotider.
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
DE69230223T2 (de) Antisense-oligonukleotid-inhibition des ras-gen
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
ATE289519T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
PT731835E (pt) Oligonucleotidos anti-sentido possuindo actividade inibidora de tumorigenicidade
DE69330372D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
DK0677056T3 (da) Oligonukleotid-alkylphosphonater og -alkylphosphonothioater
KR960704033A (ko) 인간 면역결핍 바이러스에 대한 활성을 갖는 올리고뉴클레오티드(Oligonucleotides with Activity against Humand Immunodeficiency Virus)
ES2108748T3 (es) Amplificacion de acidos nucleicos con actividad de rna polimerasa dependiente de dna, de rna replicasas.
HUP0103465A2 (hu) A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok
DE69032080D1 (de) Verwendung von konservierten Oligonukleotid-Primern zur Amplifizierung von menschlichen Papillomavirus-DNS-Sequenzen
NO965017L (no) Oligonukleotider med anti-cytomegalovirus aktivitet
NO922169L (no) Antisensoligonukleotidinhibisjon av papillomavirus
DE50303606D1 (de) Decoy-oligonukleotid-hemmung der cd40-expression